Hjem › Brystkræft › Minnesota
Brystkræft kliniske forsøg i Minnesota
68 studier for Brystkræft søger deltagere på steder i Minnesota.
Byer i Minnesota
- Rochester42 studier
- Minneapolis27 studier
- Saint Paul12 studier
- Plymouth8 studier
- Duluth7 studier
- Brooklyn Park6 studier
- Bloomington5 studier
- Mankato4 studier
- Saint Cloud4 studier
Officiel studietekst (engelsk)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Minnesota Oncology Hematology P A, Minneapolis
- Allina Hlth Cancer Inst Minneapolis, Minneapolis
RekruttererFase 3
Alder 18 til 100 · Alle køn · Opdateret 2. okt. 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- og 48 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06172478Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- Mayo Clinic in Rochester, Rochester
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alder 18 til 45 · Kvinder · Opdateret 1. okt. 2026 · NCT05557877A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Minnesota, Masonic Cancer Center, Minneapolis
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- University of Minnesota Masonic Cancer Center, Minneapolis
- Mayo Clinic Comprehensive Cancer Center, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT05868226Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Mayo Clinic, Rochester
Rekrutterer
Alder 30 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT02945579A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Saint Paul
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Mayo Clinic Cancer Center, Rochester
- HealthPartners Frauenshuh Cancer Center, Saint Louis Park
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Minneapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mayo Clinic, Rochester
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Minnesota, Rochester
- Metro-Minnesota Community Clinical Oncology, Saint Louis Park
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Mayo Clinic in Rochester, Minnesota, Rochester
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 22. sep. 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07213791Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Healthpartners Regions Specialty Clinics, Saint Louis Park
- Healthpartners Regions Specialty Clinics, Saint Paul
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Mayo Rochester, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Mayo Clinic Health System - Albert Lea, Albert Lea
- Mayo Clinic - Mankato, Mankato
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- og 2 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06492616A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Metro-Minnesota Community Oncology Research Consortium, Saint Paul
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT03424005A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Marshall, Marshall
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT07405801A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Mayo Clinic, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05307705Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07287917Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Minnesota Oncology Hematology, P.A., Minneapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- University of Minnesota Medical Center, Minneapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06790693FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07216105The Vanguard Study: Testing a New Way to Screen for Cancer
- Minneapolis VA Medical Center, Minneapolis
RekruttererFrivillige med god helbredstilstand velkomne
Alder 45 til 75 · Alle køn · Opdateret 2. sep. 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- og 47 flere
RekruttererFase 3
Alder 18 til 60 · Kvinder · Opdateret 2. sep. 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06072612Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Mayo Clinic, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06488378Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
- Mayo Clinic in Rochester, Rochester
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 til 100 · Kvinder · Opdateret 27. aug. 2026 · NCT07207564A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
- Mayo Clinic in Rochester, Rochester
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07047872Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Mayo Clinic in Rochester, Rochester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06500481A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Minnesota Oncology Hematology, Maple Grove
- Local Institution - 0372, Minneapolis
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Minnesota Oncology, Maple Grove
RekruttererFase 3
Alder 18 til 100 · Alle køn · Opdateret 6. aug. 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health Cancer Center, Duluth
- Mayo Clinic Health Systems-Mankato, Mankato
- og 1 flere
RekruttererFase 3
Alder 18 til 50 · Alle køn · Opdateret 4. aug. 2026 · NCT06748222A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
- Mayo Clinic in Rochester, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT04521764Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Mayo Clinic Rochester, Rochester
RekruttererFase 1
Alder 18 til 100 · Alle køn · Opdateret 29. jul. 2026 · NCT06562192A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.